药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Methylphenobarbital
Enzalutamide
The metabolism of Enzalutamide can be increased when combined with Docetaxel.
Methylphenobarbital
Rifamycin
The metabolism of Docetaxel can be increased when combined with Rifamycin.
Methylphenobarbital
Midostaurin
The metabolism of Docetaxel can be increased when combined with Midostaurin.
Methylphenobarbital
St. John's Wort
The metabolism of St. John's Wort can be increased when combined with Docetaxel.
Methylphenobarbital
Fenofibric acid
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Fenofibric acid.
Methylphenobarbital
Clofibride
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Clofibride.
Methylphenobarbital
Aluminium clofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Aluminium clofibrate.
Methylphenobarbital
Ronifibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Ronifibrate.
Methylphenobarbital
Simfibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Simfibrate.
Methylphenobarbital
Emetine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Emetine.
Methylphenobarbital
Ipecac
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Ipecac.
Methylphenobarbital
Mebeverine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Mebeverine.
Methylphenobarbital
Ubidecarenone
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Ubidecarenone.
Methylphenobarbital
Ciprofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Ciprofibrate.
Methylphenobarbital
Acipimox
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Acipimox.
Methylphenobarbital
Etofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Etofibrate.
Methylphenobarbital
Pitavastatin
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Pitavastatin.
Methylphenobarbital
Raltegravir
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Raltegravir.
Methylphenobarbital
Mevastatin
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Mevastatin.
Methylphenobarbital
Bezafibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Bezafibrate.